<DOC>
	<DOCNO>NCT00040599</DOCNO>
	<brief_summary>The purpose trial determine safety 90Y-hMN14 different dose level treatment colorectal cancer .</brief_summary>
	<brief_title>Safety Study 90Y-hMN14 Treat Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Disease Characteristics : Patients document histologic cytologic diagnosis colonic rectal malignancy . Patients recurrent , advance and/or metastatic disease , either fail standard therapy eligible alternate therapy higher therapeutic priority . Patients least one identify ( confirm ) measurable tumor site* tumor site &gt; 5 cm great dimension . Prior/Concurrent Therapy : Surgery : Patients exclude major surgery either within four week prior study entry . Chemotherapy : Patients must fail standard therapy eligible alternate therapy higher therapeutic priority . Patients must complete chemotherapeutic agent four week prior study entry . Biologic Therapy : Patients receive chimeric , CDRgrafted ( humanize ) , human IgG eligible provide prestudy evaluation demonstrate significant reactivity hMN14 IgG ( i.e. , HAHA ) . Radiotherapy : No prior radiotherapy within four week study entry . No prior external beam irradiation field include 30 % red marrow . No prior radiation maximal tolerable level critical organ ( e.g. , 3,000 cGy liver , 2,000 cGy lung kidney ) . Patients standard pelvic field radiation adjuvant therapy rectal carcinoma eligible MTD establish . Other : Any experimental therapy ( i.e. , drug , biologicals , procedure ) primary malignancy , either within four week prior study entry . Patient Characteristics/ Age Range : Male Female least 18 year age Performance Status : Patients Karnofsky performance status &gt; 70 % ( equivalent , ECOG 01 ) expect survival least 3 month . Hematopoietic : Hemoglobin &gt; 10 g/dL ; WBC &gt; 3000 per mm3 ; Granulocyte count &gt; 1,500 per mm3 ; Platelet count &gt; 100,000 per mm3 Hepatic : Total bilirubin &lt; 1.5 time institutional upper limit normal ( IULN ) AST ALT &lt; 2 x IULN Renal : Creatinine &lt; IULN Cardiovascular : Patients LVEF &gt; /= 50 % require MUGA/2DECHO study . Pulmonary : Patients DFCO FEV1 &gt; /= 60 % require Pulmonary Function Tests . Other : Patients prior image study murine monoclonal antibody may include . Patients agree use medically effective method contraception period three month treatment period . A pregnancy test perform premenopausal female childbearing potential immediately prior entry study . Patients able understand give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Colorectal Neoplasms</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Colorectal Tumor</keyword>
</DOC>